Argus keeps a Buy rating and $270 price target on Cencora while boosting the firm’s FY24 EPS view by 4c to $13.42 and its FY25 view by 6c to $14.76. Excluding distribution of COVID products, the company projects solid growth and margin expansion in FY24, also offering soolid growth opportunities and superior business execution, the analyst tells investors in a research note. Cencora also stands to benefit from recent acquisitions, partnerships, and strategic investments, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora raises FY24 adjusted EPS view to $13.35-$13.55 from $13.30-$13.50
- Cencora to repurchase $400M in shares from Walgreens Boots Alliance
- Walgreens Boots Alliance sells shares of Cencora for $400M
- Cencora EVP Gina K. Clark Announces Amicable Retirement
- Cencora price target raised to $277 from $275 at Baird